Edison healthcare quarterly: Evaluating risk/reward
Improved investor confidence in the biotech sector is emanating from the US, driven by increased M&A activity and speculation and the ongoing necessity for large pharma to negotiate their patent cliffs. A stock picking approach where investors evaluate assets, potential and risk/reward should enable the identification of companies with an increased likelihood of solid share price performance, with or without M&A.
Download PDF